Hepatitis B virus (HBV) infection is the main risk factor for the development and progression of hepatocellular carcinoma (HCC). Through repeated inflammatory stimulation, liver cells regeneration, fibrosis, and scar formation, it may eventually progress to HCC. Antiviral treatment reduces the incidence of HBV-related HCC and the risk of postoperative recurrence by reducing HBV DNA level, thereby improving prognosis. Many recent studies have found that different kinds of nucleos(t)ide analogues (NAs) may have differential improvements in the prevention of HBV-related HCC occurrence and postoperative recurrence. This article reviews the differential improvement of different categories of NAs in HBV-related HCC and the possible mechanisms.